What this study is
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm).
Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
The study will last approximately 48 weeks, including screening.
What's being tested
- LY4005130
Intervention · DRUG
- Placebo
Intervention · DRUG
Both interventions
Administered IV
Study details
- Official title
- A Phase 2, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Non-Segmental Vitiligo
- Sponsor
- Eli Lilly and Company
- Conditions
- Vitiligo · Non-Segmental Vitiligo (NSV)
- Enrolling
- 66 people
- Starts
- 2026-04-14
- Est. completion
- 2027-09
- Design
- Double-blind, randomized, parallel groups, Phase 2
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 75 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Eligible participants must have the following at both screening and baseline:; A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months; Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of the feet, or dorsal aspect of the feet; BSA involvement of ≥0.5% on the face; F-VASI ≥0.5 and T-VASI ≥3, and; Either active or stable disease at both screening and baseline
You can't join if
- Participants who have other types of vitiligo that are not considered active or stable vitiligo
- Currently have active forms of other disorders of pigmentation
- Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions that would interfere with evaluation of vitiligo or response to treatment
- Have a superficial skin infection within 2 weeks before baseline. Participants may be rescreened after the infection is resolved
- Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year prior to screening
- Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking the study intervention or interfere with the interpretation of data
- Any previous JAK inhibitor therapy, systemic or topical (for example, ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib) will NOT be allowed. Participant MUST be JAK inhibitor therapy-naïve
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (35)
35 openMedical Dermatology Specialists
Phoenix, Arizona, United States
- Contact602-354-5770
- Lindsay Ackerman · Principal investigator
RecruitingSaguaro Dermatology - Phoenix
Phoenix, Arizona, United States
- Contact480-562-3610
- Dathan Hamann · Principal investigator
RecruitingCenter For Dermatology Clinical Research, Inc.
Fremont, California, United States
- Contact510-797-0140
- Sunil Dhawan · Principal investigator
RecruitingNorthridge Clinical Trials
Northridge, California, United States
- Contact818-350-7482
- Navid Ezra · Principal investigator
RecruitingCura Clinical Research - Oxnard
Oxnard, California, United States
- Contact833-525-2872
- Michael Lin · Principal investigator
RecruitingCura Clinical Research - Santa Clarita - Kelly Johnson Parkway
Santa Clarita, California, United States
- Contact833-525-2872
- Bernard Raskin · Principal investigator
RecruitingHealth Clinical Research, LLC
Miami, Florida, United States
- Contact786-280-1977
- Soroush Aghigh · Principal investigator
RecruitingK2 Medical Research - Tampa
Tampa, Florida, United States
- Contact813-800-5252
- Kelley Wilson · Principal investigator
RecruitingAdvanced Medical Research, PC.
Sandy Springs, Georgia, United States
- Jamie Weisman · Principal investigator
RecruitingDawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
- Contact317-516-5030
- Scott Fretzin · Principal investigator
RecruitingBrigham and Women's Hospital
Boston, Massachusetts, United States
- Contact617-732-4918
- Arash Mostaghimi · Principal investigator
RecruitingRevival Research Institute, LLC
Troy, Michigan, United States
- Contact248-590-0298
- Ali Moiin · Principal investigator
RecruitingStracskin
Portsmouth, New Hampshire, United States
- Contact617-833-9995
- Abel Jarell · Principal investigator
RecruitingEquity Medical
The Bronx, New York, United States
- Contact332-223-6128
- Maira Fonseca · Principal investigator
RecruitingAccurate Clinical Research, Inc
Humble, Texas, United States
- Contact281-760-3930
- Chinelo Fangtang · Principal investigator
RecruitingTexas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue
San Antonio, Texas, United States
- Contact210-852-2779
- John Browning · Principal investigator
RecruitingJordan Valley Dermatology & Research Center
South Jordan, Utah, United States
- Douglass Forsha · Principal investigator
RecruitingClinical Research Partners, LLC
Richmond, Virginia, United States
- Contact804-477-3045
- Robert Call · Principal investigator
Recruiting
17 sites outside the US
- Recruiting
- Recruiting
Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman
Liège, Belgium
- Contact+3243237232
- ARJEN NIKKELS · Principal investigator
Recruiting- Recruiting
- Recruiting
Dar Clinical Research - Ottawa - Hunt Club Road
Ottawa, Canada
- Reetesh Bose · Principal investigator
RecruitingThe Centre for Dermatology
Richmond Hill, Canada
- Mani Raman · Principal investigator
Recruiting- Recruiting
- Recruiting
Peking University People's Hospital
Beijing, China
- Jianzhong Zhang · Principal investigator
RecruitingHangzhou Third People's Hospital
Hangzhou, China
- Xiuzu Song · Principal investigator
RecruitingShanghai Skin Disease Hospital
Shanghai, China
- Yuling Shi · Principal investigator
RecruitingThe University of Hong Kong-Shenzhen Hospital
Shenzhen, China
- Contact13923848084
- zhenying zhang · Principal investigator
RecruitingCentrum Badan Klinicznych PI-House sp. z o.o.
Gdansk, Poland
- Contact48513104911
- Aleksandra Okuniewska · Principal investigator
Recruiting- Recruiting
Dermedic Jacek Zdybski
Ostrowiec Świętokrzyski, Poland
- Contact786643111
- Jacek Zdybski · Principal investigator
RecruitingCentrum Medyczne Ginemedica
Wroclaw, Poland
- Justyna Kwapisz · Principal investigator
Recruiting
Study team
Sponsor
Eli Lilly and Company
Study ID 27773
Study director
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
CONTACT
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Physicians interested in becoming principal investigators please contact
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.